Strain Profile
Save
Levilactobacillus brevis CD2
◐
Food-origin
Where this strain was first isolated, curated from the literature and culture-collection catalogs. It describes provenance only — not suitability, and not benefit.
How we classify this →
Sequenced
Whether a public genome assembly is linked for this strain. Without one the genome screens cannot run. It is not a verdict on the organism.
How we classify this →
Public genome assembly available
Levilactobacillus brevis CD2 (formerly Lactobacillus brevis CD2) has a focused research record centered on oral health applications, particularly the prevention and management of oral mucositis — painful inflammation of the mouth's mucosal lining that can arise during chemotherapy and radiotherapy. Multiple randomized controlled trials have investigated CD2 lozenges in this context, as well as in dental caries risk in children and halitosis, though study sizes vary. In vitro and in vivo work has also characterized its nitrate-reducing activity, examined in relation to cardiovascular and oral health contexts. A small number of RCTs have tested it in vaginal health and respiratory infection contexts as part of multi-strain products. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 31 body-system-tagged papers that concern each system. Research coverage, not measured effect.
+2 more systems
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 22 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
35 papers reference this strain in the probiotic database.
Match confidence
How strongly this paper was matched to this strain when the corpus was linked. It orders the list — it says nothing about the study's quality or its findings.
How we classify this →
2025
RCT
2025
RCT
2025
IN_VITRO
2025
RCT
2020
RCT
2020
RCT
2020
RCT
2019
RCT
2017
RCT
2016
OBSERVATIONAL
2016
RCT
2015
OBSERVATIONAL
2015
RCT
2014
ANIMAL
2013
RCT
2013
IN_VITRO
2012
RCT
2011
RCT
2011
RCT
2007
OBSERVATIONAL
Browse all 35 papers →
The Probiotic Effects of Lactobacillus brevis CD2 on Caries Related Variables of Dental Plaque Biofilm
· International Dental Journal
Levilactobacillus brevis CD2 as a multifaceted probiotic to preserve oral health: results of a double-blind, randomized, placebo-controlled trial in healthy adults
· Journal of Translational Medicine
In Vitro, Ex Vivo, and In Vivo Evidence of Nitrate-Reducing Activity in Levilactobacillus brevis CD2: A Potential Tool for Oral and Systemic Health Applications
· Foods
Oral Probiotic Containing Streptococcus salivarius K12 and Lactobacillus brevis CD2 for Preventing Bacterial Pneumonia in Severe COVID-19: Randomized Clinical Trial
· The Journal of Contemporary Dental Practice
Effect of green tea extract mouthrinse and probiotic mouthrinse on salivary pH in a group of schoolchildren: An in vivo study
· Journal of Pharmacy And Bioallied Sciences
Lactobacillus brevis CD2 attenuates traumatic oral lesions induced by fixed orthodontic appliance: A randomized phase 2 trial
· Orthodontics and Craniofacial Research
Effect of Lactobacillus brevis CD2 containing lozenges and plaque pH and cariogenic bacteria in diabetic children: a randomised clinical trial
· Clinical Oral Investigations
Lactobacillus brevis CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study
· Anticancer Research
Long-term effect of Lactobacillus brevis CD2 (Inersan®) and/or doxycycline in aggressive periodontitis
· Journal of Indian Society of Periodontology
Lactobacillus brevis CD2 lozenges prevent oral mucositis in patients undergoing high dose chemotherapy followed by haematopoietic stem cell transplantation
· ESMO Open
Efficacy of probiotic lozenges to reduce Streptococcus mutans in plaque around orthodontic brackets
· The Journal of Indian Orthodontic Society
PTH-067 An evaluation study of lactobacillus brevis cd2 in orofacial granuolomatosis
·
Multi-Sensor Approach for the Monitoring of Halitosis Treatment via Lactobacillus brevis (CD2)—Containing Lozenges—A Randomized, Double-Blind Placebo-Controlled Clinical Trial
· Sensors
Topical treatment with probiotic Lactobacillus brevis CD2 inhibits experimental periodontal inflammation and bone loss
· Journal of Periodontal Research
Effect of a daily dose of Lactobacillus brevis CD2 lozenges in high caries risk schoolchildren
· Clinical Oral Investigations
Lactobacillus brevis CD2 inhibits Prevotella melaninogenica biofilm
· Oral Diseases
Effectiveness of vaginal tablets containing lactobacilli versus pH tablets on vaginal health and inflammatory cytokines: a randomized, double-blind study
· European Journal of Clinical Microbiology & Infectious Diseases
Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: A randomized double-blind placebo-controlled study
· European Journal of Cancer
Use of Lozenges Containing Lactobacillus brevis CD2 in Recurrent Aphthous Stomatitis: A Double-Blind Placebo-Controlled Trial
· Ulcers
Lactobacilli lozenges in the management of oral ulcers of Behçet's syndrome.
· PubMed
Discussion
Be the first to comment.
Sign in to join the discussion.
No comments yet.
Citations
Selected papers that name this strain.
-
[1]
PMID 40147282 →The Probiotic Effects of Lactobacillus brevis CD2 on Caries Related Variables of Dental Plaque Biofilm· International Dental Journal · 2025
-
[2]
PMID 39875908 →Levilactobacillus brevis CD2 as a multifaceted probiotic to preserve oral health: results of a double-blind, randomized, placebo-controlled trial in healthy adults· Journal of Translational Medicine · 2025
-
[3]
PMID 41526312 →Oral Probiotic Containing Streptococcus salivarius K12 and Lactobacillus brevis CD2 for Preventing Bacterial Pneumonia in Severe COVID-19: Randomized Clinical Trial· The Journal of Contemporary Dental Practice · 2025
-
[4]
PMID 33083852 →Effect of Lactobacillus brevis CD2 containing lozenges and plaque pH and cariogenic bacteria in diabetic children: a randomised clinical trial· Clinical Oral Investigations · 2020
-
[5]
PMID 30952736 →Lactobacillus brevis CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study· Anticancer Research · 2019
-
[6]
PMID 29456312 →Long-term effect of Lactobacillus brevis CD2 (Inersan®) and/or doxycycline in aggressive periodontitis· Journal of Indian Society of Periodontology · 2017
-
[7]
Source →Efficacy of probiotic lozenges to reduce Streptococcus mutans in plaque around orthodontic brackets· The Journal of Indian Orthodontic Society · 2016
-
[8]
Source →PTH-067 An evaluation study of lactobacillus brevis cd2 in orofacial granuolomatosis· · 2015
-
[9]
PMID 23644602 →Effect of a daily dose of Lactobacillus brevis CD2 lozenges in high caries risk schoolchildren· Clinical Oral Investigations · 2013
-
[10]
Source →Use of Lozenges Containing Lactobacillus brevis CD2 in Recurrent Aphthous Stomatitis: A Double-Blind Placebo-Controlled Trial· Ulcers · 2011